FTH.US Faeth Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
10.03 USD
Close of Nov 14, 2026
7.45 42.14
Market cap
USD 259M
P/E
-
P/B
1.71x
ROE
-164.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FTH.US undervalued?

Graham number

The Graham number of Faeth Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Faeth Therapeutics, Inc. fundamental analysis

No fundamental analysis for Faeth Therapeutics, Inc. yet.

Faeth Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes …

Full company profile